Regeneus Ltd. | Income Statement

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
1,902.00
1,820.40
1,735.50
9,994.10
575.40
Cost of Goods Sold (COGS) incl. D&A
621.50
915.40
642.50
381.30
348.00
Gross Income
1,280.50
905.00
1,093.00
9,612.80
227.40
SG&A Expense
12,410.90
10,924.30
7,536.00
8,191.60
7,546.00
EBIT
11,130.40
10,019.40
6,443.10
975.60
7,318.60
Non Operating Income/Expense
33.20
190.00
5.20
362.40
-
Interest Expense
349.20
55.40
-
16.20
25.90
Pretax Income
11,253.80
10,024.10
6,306.00
671.50
7,309.30
Income Tax
3,730.60
3,417.60
2,732.10
2,608.20
2,164.60
Equity in Affiliates
-
-
-
9.10
39.90
Consolidated Net Income
7,523.20
6,606.50
3,573.90
3,270.60
5,184.60
Net Income
7,523.20
6,606.50
3,573.90
3,270.60
5,184.60
Net Income After Extraordinaries
7,523.20
6,606.50
3,573.90
3,270.60
5,184.60
Net Income Available to Common
7,523.20
6,606.50
3,573.90
3,270.60
5,184.60
EPS (Basic)
0.05
0.03
0.02
0.02
0.02
Basic Shares Outstanding
166,539.20
204,732.40
208,885.10
208,885.10
208,885.10
EPS (Diluted)
0.05
0.03
0.02
0.02
0.02
Diluted Shares Outstanding
166,539.20
204,732.40
208,885.10
208,885.10
208,885.10
EBITDA
10,796.70
9,614.70
6,092.30
1,301.80
6,970.60
Other Operating Expense
-
-
-
445.60
-
Non-Operating Interest Income
192.60
240.70
142.30
74.50
35.10

About Regeneus

View Profile
Address
25 Bridge Street
Pymble New South Wales (NSW) 2073
Australia
Employees -
Website http://www.regeneus.com.au
Updated 07/08/2019
Regeneus Ltd. is regenerative medicine company. It develops and commercializes innovative cell-based therapies to address unmet medical needs in human and veterinary health. The company was founded by Ben Herbert and Graham Vesey on August 14, 2007 and is headquartered in Pymble, Australia.